Aligos therapeutics announces the selection of stephen harrison, md as principal investigator of ph2a study and key study design elements/milestones for nash drug candidate, alg-055009

- phase 1 study conduct complete with preliminary data indicating thr-beta agonist alg-055009 was well-tolerated with a favorable pk profile and dose responsive changes in relevant biomarkers
ALGS Ratings Summary
ALGS Quant Ranking